Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT

Inclusion Criteria

• The subject has provided written informed consent with Health Insurance Portability and Accountability Act (HIPAA) authorization before the initiation of any study-related procedures.
• The subject is at least 18 years of age at the time of consent.
• The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of Grade 0 to 2.
• The subject has a KS stage of T(0), I(0), S(0).
• The subject has a marker lesion with a confirmed diagnosis of KS (CD 206-expressing cutaneous KS) via punch biopsy. The location of the marker KS lesion will be limited to locations on the extremities: from the shoulder to the metacarpal region or from the groin to the metatarsal region.
• The subject has a marker KS lesion that is ≥ 1cm in diameter.

Exclusion Criteria

• The subject is pregnant or lactating.
• The subject has had prior chemotherapy, immunotherapy, or radiation therapy to the local KS site or regional lymphatic system within one year of enrollment.
• The subject has undergone node basin surgery of any type or radiation to the nodal basin(s) potentially draining the marker KS lesion.
• The subject has known sensitivity to dextran.